Role of the cyclin-dependent kinase inhibitor CDKN2A in familial melanoma

Journal of Cutaneous Medicine and Surgery

Volumn 2, Issue 3, 1998, Pages 172-179

  Hogg, David ^a,b   Brill, Herbert ^a   Liu, Ling ^b   Monzon, Jose ^a   Summers, Anne ^c   From, Lynn ^a   Lassam, Norman J ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c NORTH YORK GENERAL HOSPITAL   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR;

ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CANCER MORTALITY; CHROMOSOME 9P; CHROMOSOME ANALYSIS; FAMILIAL CANCER; GENE MUTATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; MELANOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0031749061     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1177/120347549800200312     Document Type: Article

References (70)

1. Norris W. A case of fungoid disease. Edinburgh Med Surg J 1820; 16:562.
2. Bale SJ, Chakravarti A, Greene MH. Cutaneous malignant melanoma and familial dysplastic nevi: evidence for autosomal dominance and pleiotrophy. Am J Hum Genet 1986; 38:188-196.
3. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68:820-823.
4. Weinberg RA. The retinoblastoma gene and gene product. Cancer Surv 1992; 12:43-57.
5. Newton JA. Familial melanoma. Clin Exp Dermatol 1993; 18:5-11.
6. Goldstein AM, Tucker MA. Genetic epidemiology of familial melanoma. Dermatol Clin 1995; 13:605-612.
7. Smith FE, Henly WS, Knox JM, Lane M. Familial melanoma. Arch Intern Med 1966; 117:820-823.
8. Whelan AJ, Bartsch D, Goodfellow PJ. A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. (Brief report) N Engl J Med 1995; 333: 975-977.
9. Lynch HT, Fusaro RM. Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 1991; 6:127-131.
10. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p161NK4 mutations. N Engl J Med 1995; 333:970-974.
11. Lucchina LC, Barnhill RL, Duke DM, Sober AJ. Familial cutaneous melanoma. Melanoma Res 1995; 5:413-418.
12. Grange E, Chompret A, Guilloud-Bataille M, et al. Comparison between familial and nonfamilial melanoma in France. Arch Dermatol 1995; 131:1154-1159.
13. Fountain JW, Bale SJ, Housman DE, Dracopoli NC. Genetics of melanoma. Cancer Surv 1990; 9:645-671.
14. Kacker RK, Giovanella BC, Pathak S. Consistent karyotypic abnormalities in human malignant melanomas. Anticancer Res 1990; 10:859-871.
15. Thompson FH, Emerson J, Olson S, et al. Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet 1995; 83:93-104.
16. Cowan JM, Francke U. Cytogenetic analysis in melanoma and nevi. Cancer Treat Res 1991; 54:3-16.
17. Cowan JM, Halaban R, Francke U. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J Natl Cancer Inst 1988; 80:1159-1164.
18. Petty EM, Gibson LH, Fountain JW, et al. Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: implications for 9p tumor-suppressor gene(s). Am J Hum Genet 1993; 53:96-104.
19. Greene MH, Goldin LR, Clark WH Jr, et al. Familial cutaneous malignant melanoma: autosomal dominant trait possibly lined to the Rh locus. Proc Natl Acad Sci USA 1983; 80:6071-6075.
20. Bale SJ, Dracopoli NC, Tucker MA, et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 1989; 320:1367-1372.
21. Goldstein AM, Dracopoli NC, Ho EC, et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet 1993; 52:537-550.
22. Gruis NA, Bergman W, Frants RR. Locus for susceptibility to melanoma on chromosome 1p. N Engl J Med 1990; 322:853-854.
23. Cannon-Albright LA, Goldgar DE, Wright EC, et al. Evidence against the reported linkage of the cutaneous melanoma-dysplastic nevus syndrome locus to chromosome 1p36. Am J Hum Genet 1990; 46:912-918.
24. Nancarrow DJ, Palmer JM, Walters MK, et al. Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm 1p in 7 Australian pedigrees. Genomics 1992; 12:18-25.
25. Goldstein AM, Goldin LR, Dracopoli NC, et al. Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi. Am J Hum Genet 1996; 58:1050-1056.
26. Walker GJ, Nancarrow DJ, Walters MK, et al. Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int J Cancer 1994; 59:771-775.
27. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992; 258:1148-1152.
28. Gruis NA, Sandkuijl LA, Weber JL, et al. Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families. Effect of naevus count. Melanoma Res 1993; 3:271-277.
29. Nancarrow DJ, Mann GJ, Holland EA, et al. Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 1993; 53:936-942.
30. Goldstein AM, Dracopoli NC, Engelstein M, et al. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet 1994; 54:489-496.
31. Bergman W, Gruis NA, Sandkuijl LA, Frants RR. Genetics of seven Dutch familial atypical multiple mole-melanoma syndrome families: a review of linkage results including chromosomes 1 and 9. J Invest Dermatol 1994; 103:122S-125S.
32. Cannon-Albright LA, Goldgar DE, Neuhausen S, et al. Localization of the 9p melanoma susceptibility locus (MLM) to a 2-cM region between D9S736 and D9S171. Genomics 1994; 23: 265-268.
33. Walker GJ, Nancarrow DJ, Palmer JM, et al. Haplorype analysis limits the position of the familial melanoma locus on 9p to the D9S169-D9S156 interval. Melanoma Res 1994; 4:29-34.
34. Weaver-Feldhaus J, Gruis NA, Neuhausen S, et al. Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. Proc Natl Acad Sci USA 1994; 91: 7563-7567.
35. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704-707.
36. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264:436-440.
37. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4A tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
38. Stone S, Jiang P, Dayananth P, et al. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 1995; 55: 2988-2994.
39. Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-1677.
40. Weinberg RA. E2F and cell proliferation: a world turned upside down. Cell 1996; 85:457-459.
41. Kamb A. Cell-cycle regulators and cancer. Trends Genet 1995; 11:136-140.
42. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9:1149-1163.
43. Beijersbergen RL, Bernards R. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochem Biophys Acta 1996; 1287:103-120.
44. Paulovich AG, Toczyski DP, Hartwell LH. When checkpoints fail. Cell 1997; 88:315-321.
45. Holland EA, Beaton SC, Becker TM, et al. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 1995; 11:2289-2294.
46. FitzGerald MG, Harkin DP, Silva-Arrieta S, et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 1996; 93:8541-8545.
47. Liu L, Lassam NJ, Slingerland JM, et al. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 1995; 11:405-412.
48. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8:15-21.
49. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994; 8:23-26.
50. MacGeoch C, Bishop JA, Bataille V, et al. Genetic heterogeneity in familial malignant melanoma. Hum Mol Genet 1994; 3: 2195-2200.
51. Reymond A, Brent R. p16 Proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene 1995; 11: 1173-1178.
52. Ranade K, Hussussian CJ, Sikorski RS, et al. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 1995; 10:114-116.
53. Parry D, Peters G. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol 1996; 16: 3844-3852.
54. Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996; 12:97-99.
55. Bataille V, Hiles R, Bishop JA. Retinoblastoma, melanoma, and the atypical mole syndrome. Br J Dermatol 1995; 132:134-138.
56. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986; 53: 661-671.
57. Traboulsi EI, Zimmerman LE, Manz HJ. Cutaneous malignant melanoma in survivors of heritable retinoblastoma. Arch Ophthalmol 1988; 106:1059-1061.
58. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993; 85:1121-1128.
59. Cannon-Albright LA, Meyer LJ, Goldgar DE, et al. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res 1994; 54:6041-6044.
60. Cannon-Albright LA, Kamb A, Skolnick M. A review of inherited predisposition to melanoma. Semin Oncol 1996; 23: 667-672.
61. Goldstein AM, Bale SJ, Tucker MA. Linkage analysis of melanoma alone and chromosome 1p markers PND, D1S47, and LMYC. Cytogenet Cell Genet 1992; 59:203-205.
62. Gruis NA, Weaver-Feldhaus J, Liu Q, et al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 1995; 146: 1199-1206.
63. Piccinin S, Doglioni C, Maestro R, et al. p16/Cdkn2 and Cdk4 gene mutations in sporadic melanoma: development and progression. Int J Cancer 1997; 74:26-30.
64. Maelandsmo GM, Florenes VA, Hovig E, et al. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumourigenesis of sporadic malignant melanomas. Br J Cancer 1996; 73: 909-916.
65. Gruis NA, van der Velden PA, Sandkuijl LA, et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 1995; 10:351-353.
66. Goldstein AM, Clark WH Jr, Fraser MC, Tucker MA. Apparent anticipation in familial melanoma. Melanoma Res 1996; 6: 441-446.
67. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994; 371:257-261.
68. Liu L, Goldstein AM, Tucker MA, et al. Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF. Genes Chromosom Cancer 1997; 19:52-54.
69. Merlo A, Herman JG, Mao L, et al. 5'CpG island methylation is associated with transcriptional silencing of the tumour supressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686-692.
70. Lalande M. Parental imprinting and human disease. Annu Rev Genet 1996; 30:173-195.